Sun Pharma's Leqselvi Boosts U.S. Innovative Sales Record

For the first time, Sun Pharmaceutical has seen its U.S. sales of innovative medicines overtake generics in the second quarter of FY26, marking a major shift for India’s largest drug maker.

 The surge came on the back of strong sales of Ilumya, psoriasis treatment; Cequa, ophthalmic product; and Odomzo, skin cancer drug.

The record performance followed the July launch of Leqselvi, Sun’s novel anti-baldness drug in the U.S., after settling a patent dispute with Incyte Corp. The company had acquired Leqselvi through its $576 million purchase of Concert Pharma.

Also Read: India's Innovative Therapies Set Global Standard at Low Cost

“Leqselvi has received an encouraging response from prescribers and patients,” Richard Ascroft, CEO of Sun Pharma's North American business, said during an investor call on Wednesday. “We anticipate access will continue to improve,” he added. “We expect to see further increases in innovative medicine sales in Q3 and Q4, especially as we launch Unloxcyt (cancer immunotherapy),” said Ascroft.

Sun Pharma’s global innovative medicines sales reached $333 million in Q2FY26, up 16.4% year-on-year, contributing 20.2% of total sales. However, overall U.S. formulation sales fell 4% to $496 million, hit by a decline in generics.

Dilip Shanghvi, Executive Chairman, Sun Pharmaceutical, said, “We continue to invest in building our R&D pipeline for our innovative medicines business.” He said the company is awaiting the FDA’s decision on the updated labeling of the cancer immunotherapy Unloxcyt and is on track to launch the drug in the U.S. in the second half of FY26.

Sun Pharma also confirmed it will be part of the first wave of generic semaglutide launches in India once Novo Nordisk’s patent expires in March. Meanwhile, it is assessing FDA’s new biosimilar guidelines before deciding on entering that market.

“In India, we will be ready for the launch in the first wave when the patent expires,” said Managing Director Kirti Ganorkar.